CU24392B1 - Compuestos y composiciones para inducir condrogénesis - Google Patents
Compuestos y composiciones para inducir condrogénesisInfo
- Publication number
- CU24392B1 CU24392B1 CU2016000169A CU20160169A CU24392B1 CU 24392 B1 CU24392 B1 CU 24392B1 CU 2016000169 A CU2016000169 A CU 2016000169A CU 20160169 A CU20160169 A CU 20160169A CU 24392 B1 CU24392 B1 CU 24392B1
- Authority
- CU
- Cuba
- Prior art keywords
- compounds
- induce
- compositions
- condrogenesis
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0655—Chondrocytes; Cartilage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
<p>La presente invención proporciona compuestos de fórmula I:</p> <p>ESPACIO PARA FÓRMULA</p> <p>o una sal farmacéuticamente aceptable, tautómero o estereoisómero del mismo, en donde las variables son como se definen en el presente documento. La presente invención proporciona además composiciones farmacéuticas que comprenden tales compuestos, y métodos de uso de tales compuestos para el tratamiento del daño en las articulaciones o lesión de Ia articulación en un mamífero, y para inducir Ia diferenciación de células madre mesenquimales en condrocitos.</p>
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461992815P | 2014-05-13 | 2014-05-13 | |
PCT/US2015/030303 WO2015175487A1 (en) | 2014-05-13 | 2015-05-12 | Compounds and compositions for inducing chondrogenesis |
Publications (2)
Publication Number | Publication Date |
---|---|
CU20160169A7 CU20160169A7 (es) | 2017-05-10 |
CU24392B1 true CU24392B1 (es) | 2019-04-04 |
Family
ID=53284520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2016000169A CU24392B1 (es) | 2014-05-13 | 2015-05-12 | Compuestos y composiciones para inducir condrogénesis |
Country Status (30)
Country | Link |
---|---|
US (6) | US9688689B2 (es) |
EP (1) | EP3143026A1 (es) |
JP (1) | JP6479051B2 (es) |
KR (1) | KR102375396B1 (es) |
CN (1) | CN106459076B (es) |
AP (1) | AP2016009502A0 (es) |
AR (1) | AR100418A1 (es) |
AU (1) | AU2015259403B2 (es) |
BR (1) | BR112016025659B1 (es) |
CA (1) | CA2947031C (es) |
CL (1) | CL2016002838A1 (es) |
CR (1) | CR20160528A (es) |
CU (1) | CU24392B1 (es) |
EA (1) | EA031609B1 (es) |
HK (1) | HK1231467A1 (es) |
IL (1) | IL248400B (es) |
JO (1) | JO3563B1 (es) |
MA (1) | MA39972A (es) |
MX (1) | MX2016014854A (es) |
MY (1) | MY186570A (es) |
NZ (1) | NZ725044A (es) |
PE (1) | PE20161432A1 (es) |
PH (1) | PH12016502005A1 (es) |
SG (1) | SG11201608823RA (es) |
SV (1) | SV2016005316A (es) |
TN (1) | TN2016000441A1 (es) |
TW (1) | TWI662039B (es) |
UY (1) | UY36118A (es) |
WO (1) | WO2015175487A1 (es) |
ZA (1) | ZA201606929B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014151953A1 (en) | 2013-03-15 | 2014-09-25 | The California Institute For Biomedical Research | Compounds and methods for inducing chondrogenesis |
NZ725044A (en) * | 2014-05-13 | 2019-03-29 | Novartis Ag | Compounds and compositions for inducing chondrogenesis |
CN109963579A (zh) * | 2016-11-14 | 2019-07-02 | 诺华股份有限公司 | 用于治疗软骨损伤和关节炎的方法和组合物 |
AU2018257769A1 (en) * | 2017-04-24 | 2019-11-07 | The Scripps Research Institute | Methods for inducing chondrogenesis |
JOP20190282A1 (ar) | 2017-06-09 | 2019-12-05 | Novartis Ag | مركبات وتركيبات لحث تكوّن الغضاريف |
JP7284750B2 (ja) * | 2017-11-10 | 2023-05-31 | ノバルティス アーゲー | 関節内適用のための持続放出製剤 |
AU2019309727B2 (en) | 2018-07-25 | 2021-12-23 | Novartis Ag | NLRP3 inflammasome inhibitors |
WO2020115683A1 (en) | 2018-12-06 | 2020-06-11 | Novartis Ag | 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage |
WO2020115684A1 (en) | 2018-12-06 | 2020-06-11 | Novartis Ag | 6-hydroxy-8-oxatricyclo[3.2.1.02,4]octane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage |
WO2020124500A1 (zh) * | 2018-12-20 | 2020-06-25 | 江苏凯迪恩医药科技有限公司 | 一种含氮杂环化合物、其制备方法及应用 |
AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
RU2733472C1 (ru) * | 2020-02-26 | 2020-10-01 | Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) | N-Ацилгидразон фенхона с фрагментом эпоксиизоиндола, используемый в качестве ингибитора репродукции вируса Хантаан |
CN114763347A (zh) * | 2021-01-15 | 2022-07-19 | 华东师范大学 | 一类用于诱导间充质干细胞向软骨分化的化合物及其应用 |
US20240067627A1 (en) | 2022-08-03 | 2024-02-29 | Novartis Ag | Nlrp3 inflammasome inhibitors |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2205274B1 (es) | 1972-11-02 | 1976-10-01 | Sumitomo Chemical Co | |
US3925554A (en) | 1972-11-30 | 1975-12-09 | Sumitomo Chemical Co | Certain 3,5-dichlorophenyl compound used as a plant fungicide |
US4687865A (en) | 1986-06-04 | 1987-08-18 | E. R. Squibb & Sons, Inc. | Process for preparing 7-oxabicycloheptane amino-alcohol intermediates useful in making thromboxane A2 receptor antagonists |
US4707494A (en) | 1986-08-26 | 1987-11-17 | E. R. Squibb & Sons, Inc. | 7-oxabicyclo(2.2.1)heptane compounds useful in the treatment of inflammation |
JP2984077B2 (ja) | 1990-04-19 | 1999-11-29 | 塩野義製薬株式会社 | スルホニルアミノ置換ビシクロ環系ヒドロキサム酸誘導体 |
US5126370A (en) | 1990-12-24 | 1992-06-30 | E. R. Squibb & Sons, Inc. | Anti-thrombotic heterocyclic amido prostaglandin analogs |
JPH04275182A (ja) | 1991-03-01 | 1992-09-30 | Sankyo Kagaku Kk | 感熱転写記録用色素 |
US5506242A (en) | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
US5399725A (en) | 1993-05-27 | 1995-03-21 | Bristol-Myers Squibb Co. | 7-oxabicycloheptane carboxylic acid prostaglandin analog intermediates useful in the preparation of anti-thrombotic and anti-vasospastic compounds and method for preparing same |
WO1995007078A1 (en) | 1993-09-10 | 1995-03-16 | Cytomed, Inc. | Epibatidine and derivatives thereof as cholinergic receptor agonists and antagonists |
US5529925A (en) | 1993-12-03 | 1996-06-25 | St. Jude Children's Research Hospital | Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma |
US5416106A (en) | 1993-12-28 | 1995-05-16 | Allergan, Inc. | 7-[carboxyalkyl or alkenyl]-6-[alkyl or alkenyl]3-oxo-2,4-dioxobicyclo-[3.2.1] octane and derivatives thereof |
US6017953A (en) | 1993-12-28 | 2000-01-25 | Allergan Sales, Inc. | Thromboxane ligands |
FR2718136B1 (fr) | 1994-03-29 | 1996-06-21 | Sanofi Sa | Composés aromatiques aminés, procédé pour leur obtention et compositions pharmaceutiques les contenant. |
US6447796B1 (en) | 1994-05-16 | 2002-09-10 | The United States Of America As Represented By The Secretary Of The Army | Sustained release hydrophobic bioactive PLGA microspheres |
EP0912170A4 (en) | 1996-05-02 | 2003-04-09 | Merck & Co Inc | HIV PROTEASE INHIBITORS USEFUL IN AIDS TREATMENT |
PT950059E (pt) | 1997-01-06 | 2004-10-29 | Pfizer | Derivados de sulfona ciclicos |
AU767195B2 (en) | 1999-03-10 | 2003-11-06 | Phogen Limited | Delivery of substances to cells |
GB9908021D0 (en) * | 1999-04-08 | 1999-06-02 | Lilly Co Eli | Pharmaceutical compounds |
WO2000066577A2 (en) | 1999-04-29 | 2000-11-09 | Allergan Sales, Inc. | Brigded cycloalkanes as thromboxane ligands without blood clotting effects |
JP2003518494A (ja) | 1999-12-29 | 2003-06-10 | グラクソ グループ リミテッド | アネキシンおよび軟骨ホメオスタシスのモジュレーターに関係する方法と組成物 |
US20040077605A1 (en) | 2001-06-20 | 2004-04-22 | Salvati Mark E. | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
CN1213050C (zh) * | 2000-11-23 | 2005-08-03 | 拜尔公司 | 氧杂双环[2.2.1]庚烷衍生物,其制备方法和作为农药的用途 |
US20020130430A1 (en) | 2000-12-29 | 2002-09-19 | Castor Trevor Percival | Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products |
MXPA03006524A (es) | 2001-02-16 | 2003-09-25 | Aventis Pharma Inc | Derivados heterociclicos novedosos de amidas y su uso como ligandos para receptor d3 de dopamina. |
US7060498B1 (en) | 2001-11-28 | 2006-06-13 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
US7141540B2 (en) | 2001-11-30 | 2006-11-28 | Genta Salus Llc | Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof |
EP1478646A1 (en) | 2002-02-20 | 2004-11-24 | PHARMACIA & UPJOHN COMPANY | Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity |
EP1388535A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylated arylcycloalkylamines and their use as pharmaceuticals |
CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
AU2004216898A1 (en) | 2003-03-04 | 2004-09-16 | Pfizer Products Inc. | Use of EP2 selective receptor agonists in medical treatment |
JP4666257B2 (ja) | 2003-07-25 | 2011-04-06 | 小野薬品工業株式会社 | 軟骨関連疾患治療剤 |
JP2005097195A (ja) | 2003-09-25 | 2005-04-14 | Institute Of Physical & Chemical Research | 医薬組成物 |
WO2005047383A1 (en) | 2003-11-07 | 2005-05-26 | Milliken & Company | Concentrates of saturated bicyclic dicarboxylate salts as polymer nucleation additives and methods of nucleating thermoplastics |
EP2708541B1 (en) | 2003-11-13 | 2015-01-28 | Isis Pharmaceuticals, Inc. | 5,6-dihydroxy-isoindole derivatives as linkers for oligomer solid phase synthesis |
US20050203086A1 (en) | 2004-03-04 | 2005-09-15 | Pfizer Inc. | Methods of treatment using an EP2 selective receptor agonist |
EP1792622A1 (en) * | 2005-11-11 | 2007-06-06 | GPC Biotech AG | Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and EGFR inhibitors or pyrimidine analogues |
US7795370B2 (en) | 2005-11-15 | 2010-09-14 | Mitsubishi Chemical Corporation | Tetracarboxylic acid compound, polyimide thereof, and production method thereof |
GB0526240D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
US7566797B2 (en) | 2006-03-03 | 2009-07-28 | Milliken & Company | Metal carboxylate salt nucleating or clarifying agent compounds and related polymer compositions and methods |
CN101662939B (zh) | 2007-02-06 | 2015-11-25 | 利克斯特生物技术公司 | 氧杂双环庚烷和氧杂双环庚烯,它们的制备及用途 |
JP4275182B2 (ja) | 2007-11-02 | 2009-06-10 | シャープ株式会社 | 熱交換器 |
EP2309853A4 (en) | 2008-08-01 | 2012-04-25 | Lixte Biotechnology Inc | METHOD FOR CELL MITITULATING BY INHIBITION OF SERIN / THREONINE PHOSPHATASE |
US8227473B2 (en) | 2008-08-01 | 2012-07-24 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
WO2010014220A1 (en) | 2008-08-01 | 2010-02-04 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
US8455477B2 (en) * | 2008-08-05 | 2013-06-04 | Merck Sharp & Dohme Corp. | Therapeutic compounds |
WO2010099573A1 (en) | 2009-03-03 | 2010-09-10 | Deakin University | Dioxolane norbornane / norbornene compounds suitable as antimicrobial agents to treat bacterial infections |
AU2010232556A1 (en) * | 2009-04-02 | 2011-11-03 | Allergan, Inc. | Prostaglandin E receptor antagonists |
AU2010250789B2 (en) | 2009-05-18 | 2015-05-14 | Actelion Pharmaceuticals Ltd | Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists |
EP2453921B1 (en) | 2009-07-14 | 2015-05-27 | The Scripps Research Institute | Mesenchymal stem cell differentiation |
CN101628951B (zh) * | 2009-08-12 | 2011-06-22 | 中国石油天然气股份有限公司 | 烯烃聚合用固体催化组分及其催化剂 |
JP5478161B2 (ja) | 2009-09-03 | 2014-04-23 | 株式会社クラレ | アクリル酸エステル誘導体およびアルコール誘導体並びにそれらの製造方法 |
CA2789879A1 (en) | 2009-10-28 | 2011-05-19 | Joyant Pharmaceuticals, Inc. | Dimeric smac mimetics |
US8754059B2 (en) | 2010-02-16 | 2014-06-17 | University Of Miami | Use of miR-30e to treat vascular lesions |
CA2803920A1 (en) | 2010-06-24 | 2011-12-29 | Richard Beard | Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity |
JP5917541B2 (ja) | 2010-11-17 | 2016-05-18 | アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd | 架橋スピロ[2.4]ヘプタンエステル誘導体 |
WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
CA2836940A1 (en) | 2011-05-24 | 2012-11-29 | Lixte Biotechnology, Inc. | Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein function |
MA37618B1 (fr) | 2012-05-16 | 2017-08-31 | Actelion Pharmaceuticals Ltd | Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx |
CN104284887B (zh) | 2012-05-16 | 2016-06-22 | 埃科特莱茵药品有限公司 | 作为alx受体激动剂的经1-(对-甲苯基)环丙基取代的桥联螺[2.4]庚烷衍生物 |
AU2013282365A1 (en) | 2012-06-29 | 2015-02-19 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes |
CA2876703A1 (en) | 2012-06-29 | 2014-01-03 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of reperfusion injury |
KR20160004299A (ko) | 2013-04-09 | 2016-01-12 | 릭스트 바이오테크놀로지, 인코포레이티드 | 옥사바이시클로헵탄류 및 옥사바이시클로헵텐류의 제형 |
AR096686A1 (es) | 2013-06-25 | 2016-01-27 | Actelion Pharmaceuticals Ltd | Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx |
AU2014292064B2 (en) | 2013-07-18 | 2018-07-05 | Idorsia Pharmaceuticals Ltd | Piperazine substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists |
NZ725044A (en) * | 2014-05-13 | 2019-03-29 | Novartis Ag | Compounds and compositions for inducing chondrogenesis |
-
2015
- 2015-05-12 NZ NZ725044A patent/NZ725044A/en unknown
- 2015-05-12 CR CR20160528A patent/CR20160528A/es unknown
- 2015-05-12 TN TN2016000441A patent/TN2016000441A1/en unknown
- 2015-05-12 UY UY0001036118A patent/UY36118A/es active IP Right Grant
- 2015-05-12 TW TW104115093A patent/TWI662039B/zh active
- 2015-05-12 JO JOP/2015/0112A patent/JO3563B1/ar active
- 2015-05-12 AU AU2015259403A patent/AU2015259403B2/en active Active
- 2015-05-12 PE PE2016002192A patent/PE20161432A1/es unknown
- 2015-05-12 JP JP2016567425A patent/JP6479051B2/ja active Active
- 2015-05-12 CU CU2016000169A patent/CU24392B1/es unknown
- 2015-05-12 AP AP2016009502A patent/AP2016009502A0/en unknown
- 2015-05-12 WO PCT/US2015/030303 patent/WO2015175487A1/en active Application Filing
- 2015-05-12 MX MX2016014854A patent/MX2016014854A/es active IP Right Grant
- 2015-05-12 US US14/709,852 patent/US9688689B2/en active Active
- 2015-05-12 KR KR1020167031308A patent/KR102375396B1/ko active IP Right Grant
- 2015-05-12 MY MYPI2016703716A patent/MY186570A/en unknown
- 2015-05-12 SG SG11201608823RA patent/SG11201608823RA/en unknown
- 2015-05-12 CA CA2947031A patent/CA2947031C/en active Active
- 2015-05-12 EA EA201692292A patent/EA031609B1/ru not_active IP Right Cessation
- 2015-05-12 BR BR112016025659-0A patent/BR112016025659B1/pt active IP Right Grant
- 2015-05-12 CN CN201580022603.4A patent/CN106459076B/zh active Active
- 2015-05-12 EP EP15727117.2A patent/EP3143026A1/en active Pending
- 2015-05-12 MA MA039972A patent/MA39972A/fr unknown
- 2015-05-13 AR ARP150101470A patent/AR100418A1/es unknown
-
2016
- 2016-10-10 PH PH12016502005A patent/PH12016502005A1/en unknown
- 2016-10-10 ZA ZA2016/06929A patent/ZA201606929B/en unknown
- 2016-10-19 IL IL248400A patent/IL248400B/en active IP Right Grant
- 2016-11-09 CL CL2016002838A patent/CL2016002838A1/es unknown
- 2016-11-11 SV SV2016005316A patent/SV2016005316A/es unknown
-
2017
- 2017-05-05 US US15/587,652 patent/US10188638B2/en active Active
- 2017-05-17 HK HK17104956.5A patent/HK1231467A1/zh unknown
-
2018
- 2018-11-28 US US16/203,122 patent/US10383863B2/en active Active
-
2019
- 2019-06-21 US US16/448,547 patent/US10660881B2/en active Active
-
2020
- 2020-04-14 US US16/848,568 patent/US11510912B2/en active Active
-
2022
- 2022-10-19 US US18/048,016 patent/US20230112980A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU24392B1 (es) | Compuestos y composiciones para inducir condrogénesis | |
CL2016003293A1 (es) | Inhibidores de mnk y método relacionado al mismo | |
CL2017001572A1 (es) | Compuestos de triazolopirimidina y usos de los mismos. | |
CR20160212A (es) | Composiciones y métodos para modular los receptores x farnesoides | |
CL2016002091A1 (es) | Compuesto de triazina y su uso para fines medicinales | |
CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
UY36342A (es) | Nuevos derivados de aminoalquilbenzotiazepinas y usos de los mismos | |
UY34750A (es) | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. | |
CO2017003279A2 (es) | Compuestos y composiciones farmacéuticamente aceptables de los mismos, eficaces como inhibidores de mk2 | |
PE20150631A1 (es) | Formas cristalinas de un modulador del receptor androgenico | |
CL2015002546A1 (es) | Derivados 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftálmicos | |
CU20170007A7 (es) | Compuestos de imidazopiridazina | |
UY36287A (es) | COMPUESTO DE OBJETIVO A IL-23A y TNF-ALFA Y USO DEL MISMO | |
SV2016005293A (es) | Compuestos de azol amido-sustituidos como inhibidores de tnks1 y/o tnks2 | |
CR20150653A (es) | Compuestos nuevos para el tratamiento del cáncer | |
NZ730195A (en) | Heterocyclic compounds and use thereof | |
BR112018008931A2 (pt) | ?compostos para tratamento de distúrbios hipoproliferativos? | |
UY37759A (es) | Compuestos y composiciones para inducir condrogénesis | |
EA201650003A1 (ru) | Соединённые циклоалкилом дигетероциклические производные | |
CL2017000242A1 (es) | Compuestos de imidazopiridazina | |
GT201500232A (es) | Compuestos de azabencimidazol como inhibidores de las isozimas pde4 para el tratamiento de cns y otros trastornos | |
ECSP17003149A (es) | Compuestos de dihidroisoquinolinona sustituida |